^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AVX901

    i
    Other names: DUKE-002-VRP, VRP HER2 ECDTM, HUHER2-ECD+TM, HER2 VRP, HER2 ECDTM VRP, AVX901, AVX 901, VRP-HER2, VRP-HER2 ECDTM
    Associations

    News

    Trials
    Company:
    AlphaVax
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    12ms
    A Study to Evaluate Concurrent VRP-HER2 Vaccination and Pembrolizumab for Patients With Breast Cancer (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, Herbert Lyerly | Recruiting --> Active, not recruiting | N=39 --> 9
    Enrollment closed • Enrollment change • Metastases
    |
    Keytruda (pembrolizumab) • AVX901
    3years
    Immunotherapy for the Breast Cancer treatment: Current Evidence and Therapeutic Options. (PubMed, Endocr Metab Immune Disord Drug Targets)
    Although, commonly used treatments like trastuzumab/pertuzumab for human epidermal growth factor receptor 2 (Her2) positive and hormone therapy for estrogen receptor (ER) positive and/or progesterone receptor (PR) positive BC are specific but triple negative breast cancer (TNBC) cases remain a great challenge for treatment measures. Immune checkpoint inhibitors (anti-PD-1/ anti-CTLA-4) and anti-cancer vaccines (NeuVax, Muc-1, AVX901, INO-1400 and CEA), either alone or in combination with other therapies have created new paradigm in therapeutic world. In this review, we highlighted the current immunotherapeutic aspects and their ongoing trials towards the better treatment regimen for BC.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MUC1 (Mucin 1)
    |
    ER positive • EGFR positive
    |
    Herceptin (trastuzumab) • Perjeta (pertuzumab) • AVX901 • INO-1400 • NeuVax (nelipepimut-S)